Cargando…

Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades

Objectives: Pharmacoeconomics evaluation (PE) is increasingly used in the healthcare decision-making process in China. Little is known about PE conducted in Chinese Herbal Medicines (CHMs). We aimed to systematically review trends, characteristics, and quality of PE of CHMS. Methods: We systematical...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Xiaomo, Jiang, Xiangxiang, Lv, Gang, Yuan, Jing, Li, Minghui, Lu, Z. Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117622/
https://www.ncbi.nlm.nih.gov/pubmed/35600881
http://dx.doi.org/10.3389/fphar.2022.765226
_version_ 1784710348958334976
author Xiong, Xiaomo
Jiang, Xiangxiang
Lv, Gang
Yuan, Jing
Li, Minghui
Lu, Z. Kevin
author_facet Xiong, Xiaomo
Jiang, Xiangxiang
Lv, Gang
Yuan, Jing
Li, Minghui
Lu, Z. Kevin
author_sort Xiong, Xiaomo
collection PubMed
description Objectives: Pharmacoeconomics evaluation (PE) is increasingly used in the healthcare decision-making process in China. Little is known about PE conducted in Chinese Herbal Medicines (CHMs). We aimed to systematically review trends, characteristics, and quality of PE of CHMS. Methods: We systematically searched both Chinese (CNKI, WanFang, and VIP) and English (Pubmed) databases. Studies were included if they were PE studies comparing both costs and outcomes between two or more interventions published in Chinese or English. Assessment of the quality of studies was conducted using the Quality of Health Economic Analyses (QHES) instrument. T-test and Chi-square tests were used to compare the studies before and after the first edition of China Guidelines for PE published in 2011, and between studies published in Chinese and English. Results: A total of 201 articles were included. There was an increasing trend of PE studies on CHMs during the study period. The top three studied diseases were central nervous system (CNS), mental, and behavioral disorders; cardiovascular diseases; and blood, immune and endocrine diseases. The average QHES score for the included studies was 63.37. Cost-effectiveness analysis (CEA) accounted for the majority (76.6%) of the included studies. Only a quarter of the articles (27.4%) were funded, and there were significantly more studies funded after the publication of China guidelines for PE. About 96.5% of studies did not specify evaluation perspectives and 89.6% of studies had a sample size of less than 300. Around half of the studies (55%) used incremental analysis, but only a few of them considered using a threshold. Half of the studies lacked sensitivity analysis. There was no significant improvement in the quality of studies published after the publication of China Guidelines for PE, and English articles had significantly higher quality than Chinese articles. Conclusion: This study identified several problems in PE studies on CHMs, including having small sample sizes, lacking necessary research elements, and using single evaluation methods. The quality of PE studies on CHMs was not sufficient. Researchers need to understand the standardized way to conduct PE studies and improve the quality and level of PE studies on CHMs.
format Online
Article
Text
id pubmed-9117622
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91176222022-05-20 Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades Xiong, Xiaomo Jiang, Xiangxiang Lv, Gang Yuan, Jing Li, Minghui Lu, Z. Kevin Front Pharmacol Pharmacology Objectives: Pharmacoeconomics evaluation (PE) is increasingly used in the healthcare decision-making process in China. Little is known about PE conducted in Chinese Herbal Medicines (CHMs). We aimed to systematically review trends, characteristics, and quality of PE of CHMS. Methods: We systematically searched both Chinese (CNKI, WanFang, and VIP) and English (Pubmed) databases. Studies were included if they were PE studies comparing both costs and outcomes between two or more interventions published in Chinese or English. Assessment of the quality of studies was conducted using the Quality of Health Economic Analyses (QHES) instrument. T-test and Chi-square tests were used to compare the studies before and after the first edition of China Guidelines for PE published in 2011, and between studies published in Chinese and English. Results: A total of 201 articles were included. There was an increasing trend of PE studies on CHMs during the study period. The top three studied diseases were central nervous system (CNS), mental, and behavioral disorders; cardiovascular diseases; and blood, immune and endocrine diseases. The average QHES score for the included studies was 63.37. Cost-effectiveness analysis (CEA) accounted for the majority (76.6%) of the included studies. Only a quarter of the articles (27.4%) were funded, and there were significantly more studies funded after the publication of China guidelines for PE. About 96.5% of studies did not specify evaluation perspectives and 89.6% of studies had a sample size of less than 300. Around half of the studies (55%) used incremental analysis, but only a few of them considered using a threshold. Half of the studies lacked sensitivity analysis. There was no significant improvement in the quality of studies published after the publication of China Guidelines for PE, and English articles had significantly higher quality than Chinese articles. Conclusion: This study identified several problems in PE studies on CHMs, including having small sample sizes, lacking necessary research elements, and using single evaluation methods. The quality of PE studies on CHMs was not sufficient. Researchers need to understand the standardized way to conduct PE studies and improve the quality and level of PE studies on CHMs. Frontiers Media S.A. 2022-05-05 /pmc/articles/PMC9117622/ /pubmed/35600881 http://dx.doi.org/10.3389/fphar.2022.765226 Text en Copyright © 2022 Xiong, Jiang, Lv, Yuan, Li and Lu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Xiong, Xiaomo
Jiang, Xiangxiang
Lv, Gang
Yuan, Jing
Li, Minghui
Lu, Z. Kevin
Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades
title Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades
title_full Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades
title_fullStr Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades
title_full_unstemmed Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades
title_short Evidence of Chinese Herbal Medicine Use From an Economic Perspective: A Systematic Review of Pharmacoeconomics Studies Over Two Decades
title_sort evidence of chinese herbal medicine use from an economic perspective: a systematic review of pharmacoeconomics studies over two decades
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117622/
https://www.ncbi.nlm.nih.gov/pubmed/35600881
http://dx.doi.org/10.3389/fphar.2022.765226
work_keys_str_mv AT xiongxiaomo evidenceofchineseherbalmedicineusefromaneconomicperspectiveasystematicreviewofpharmacoeconomicsstudiesovertwodecades
AT jiangxiangxiang evidenceofchineseherbalmedicineusefromaneconomicperspectiveasystematicreviewofpharmacoeconomicsstudiesovertwodecades
AT lvgang evidenceofchineseherbalmedicineusefromaneconomicperspectiveasystematicreviewofpharmacoeconomicsstudiesovertwodecades
AT yuanjing evidenceofchineseherbalmedicineusefromaneconomicperspectiveasystematicreviewofpharmacoeconomicsstudiesovertwodecades
AT liminghui evidenceofchineseherbalmedicineusefromaneconomicperspectiveasystematicreviewofpharmacoeconomicsstudiesovertwodecades
AT luzkevin evidenceofchineseherbalmedicineusefromaneconomicperspectiveasystematicreviewofpharmacoeconomicsstudiesovertwodecades